METHOXPHENIDINE, A DESIGNER DRUG OR A POSSIBLE ROUTE FOR RESEARCH TO DEPRESSION TREATMENT?
International Journal of Neuropsychopharmacology February 12, 2025 *Bronislav Jurásek, Magdaléna Vágnerová, Hana Walaská et al.
Methoxphenidine (MXP), a dissociative new psychoactive substance related to ketamine, was studied in rats to determine its behavioral and pharmacokinetic effects. MXP at 60 mg/kg was administered subcutaneously, and urine was analyzed to identify metabolites. In behavioral tests, doses of 10, 20, and 40 mg/kg were given. Lower doses (10 and 20 mg/kg) produced significant locomotor stimulation, while the highest dose (40 mg/kg) increased time spent in the center of an open field, suggesting sedative effects. Maximal effects occurred about 30 minutes after administration, with peak blood and brain concentrations around 1 hour. The pharmacokinetic profile indicates slower metabolism and excretion of MXP compared to ketamine. Further research is needed to explore potential antidepressant properties.